Health Condition 1: E119- Type 2 diabetes mellitus without complications
Conditions
Interventions
Intervention1: Lobeglitazone: patients will receive lobeglitazone 0.5mg per day
Control Intervention1: Pioglitazone: Patients will receive pioglitazone 15 to 30mg per day
Sponsors
Dr Arindam Naskar
Eligibility
Inclusion criteria
Inclusion criteria: Type 2 diabetes mellitus with HbA1c between 7 to 9 Willing to provide informed consent
Exclusion criteria
Exclusion criteria: Pregnancy or breast feeding Patient with eGFR less than 45 mL/min Patients with cardiac rhythm disorders or heart failure Baseline AST and ALT more than 3 times of upper limit Patient with BMI more than 40 Patient with hemoglobin less than 8g/dL History of any spine fractures Patients with malignancies Patients on insulin, SGLT 2i and GLP 1 agonist therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effect of lobeglitazone vs pioglitazone on arterial stiffness as an add on therapy to preexisting anti diabetic drugs in patients with type 2 diabetesTimepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c, fasting blood sugar, post prandial blood sugarTimepoint: 6 months;Proportion of patients acheiving HbA1c less than 7 percentageTimepoint: 6 months | — |
Countries
India
Contacts
Public ContactDr Arindam Naskar
School of Tropical Medicine
Outcome results
None listed